Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.37 |
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.36 |
| ▸ | WNT3A | P56704 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776227 | 0.89 | FGFR4 (0.37) | FGFR4RPS6KA2WNT3AABL1MAPK1 | |
| SCHEMBL16776016 | 0.87 | WNT3A (0.40) | CYP11B2WNT3AABL1MAPK1GRM5 | |
| SCHEMBL16775917 | 0.86 | GRM5 (0.40) | FGFR4RPS6KA2MAPK1MAPTGRM5 | |
| SCHEMBL16776109 | 0.85 | KARS1 (0.38) | FGFR4ABL1MAPK1MAPTGRM5 | |
| SCHEMBL19365504 | 0.85 | CYP11B2 (0.37) | CYP11B2FGFR4WNT3ACYP3A4ROCK1 | |
| SCHEMBL16775996 | 0.83 | DYRK1A (0.43) | — | |
| SCHEMBL19670435 | 0.83 | WNT3A (0.36) | CYP11B2FGFR4WNT3ACYP3A4ROCK1 | |
| SCHEMBL16776013 | 0.83 | FGFR4 (0.44) | FGFR4RPS6KA2WNT3AMAPK1GRM5 | |
| SCHEMBL16776025 | 0.82 | CYP11B2 (0.38) | CYP11B2WNT3AMAPK1GRM5 | |
| SCHEMBL16776226 | 0.81 | HTR2C (0.45) | CYP3A4ABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP11B2 1166/4885FGFR4 1754/4885RPS6KA2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.